- Home
- CLDI
as 04-23-2025 4:00pm EST
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 14.0M | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 386.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $4.90 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Calidi Biotherapeutics Inc. News
CLDI Breaking Stock News: Dive into CLDI Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 hours ago
Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director
GlobeNewswire
2 days ago
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
GlobeNewswire
7 days ago
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
GlobeNewswire
14 days ago
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
GlobeNewswire
23 days ago
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
GlobeNewswire
24 days ago
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights
GlobeNewswire
a month ago
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
GlobeNewswire
a month ago
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
Compare CLDI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLDI Calidi Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.